Fair Pricing of Innovative Medicines: An EHA Position Paper

Affiliations

¹ Department of Hematology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
² Barts Cancer Institute, Queen Mary University of London, London, UK.
³ Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, and Comprehensive Cancer Center, Vienna, Austria.
⁴ Inspire2Live, Amsterdam, The Netherlands.
⁵ Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, University of Pavia, Italy.
⁶ PNH Support, a Charitable Incorporated Organization registered with the Charities Commission of England and Wales (no. 1161518), London, UK.
⁷ Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands.
⁸ Institute for Medical Technology Assessment, Rotterdam, The Netherlands.
⁹ European Hematology Association, The Hague, The Netherlands.

Editorial

Anton Hagenbeek et al. Hemasphere. 2020.

. 2020 Sep 30;4(5):e488.

doi: 10.1097/HS9.0000000000000488. eCollection 2020 Oct.

¹ Department of Hematology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
² Barts Cancer Institute, Queen Mary University of London, London, UK.
³ Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, and Comprehensive Cancer Center, Vienna, Austria.
⁴ Inspire2Live, Amsterdam, The Netherlands.
⁵ Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, University of Pavia, Italy.
⁶ PNH Support, a Charitable Incorporated Organization registered with the Charities Commission of England and Wales (no. 1161518), London, UK.
⁷ Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands.
⁸ Institute for Medical Technology Assessment, Rotterdam, The Netherlands.
⁹ European Hematology Association, The Hague, The Netherlands.

No abstract available

References

1. Green T, Bron D, Chomienne C, et al. Costs of haematological disease high and rising. Lancet Haematol. 2016;3:e353–e354. - PubMed
1. See for a comprehensive overview of challenges and recommended actions the European Parliament resolution of 2 March 2017 on EU options for improving access to medicines (2016/2057(INI). European Parliament. 2017. https://www.europarl.europa.eu/doceo/document/TA-8-2017-0061_EN.html. Accessed August 4, 2020.
1. A collaboration of Belgium, the Netherlands, Luxemburg, Austria and Ireland. For an excellent analysis of the Beneluxa Initiative, see: Natsis Y. European Public Health Alliance. BeNeLuxA et al.: the best is yet to come. 2019. https://epha.org/beneluxa-best-is-yet-to-come/. Accessed August 4, 2020.
1. For the positions of EHA and the BioMed Alliance, seehttps://ehaweb.org/organization/newsroom/news-and-updates/health-technol... and https://www.biomedeurope.org/news/2019/160-medical-societies-urge-member.... European Commission. Proposal for a regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU. 2018. https://ec.europa.eu/health/sites/health/files/technology_assessment/doc.... Accessed August 4, 2020.
1. Hagenbeek T, Engert A, Kapitein P, et al. Affordability of medicines a top priority for EHA: toward a fair pricing model for innovative medicines. HemaSphere. 2017;1:e12. - PMC - PubMed